As of 2024-12-11, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (4,924.97) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -58040.9%.
The range of the Relative Valuation is (4,607.84) - (4,309.62) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.9x - 32.0x | 27.0x |
| Forward P/E multiples | 19.4x - 20.5x | 20.0x |
| Fair Price | (4,607.84) - (4,309.62) | (4,924.97) |
| Upside | -54309.9% - -50801.4% | -58040.9% |
| Date | P/E |
| 2024-09-30 | -0.04 |
| 2024-09-27 | -0.04 |
| 2024-09-26 | -0.04 |
| 2024-09-25 | -0.04 |
| 2024-09-24 | -0.04 |
| 2024-09-23 | -0.04 |
| 2024-09-19 | -0.04 |
| 2024-09-18 | -0.04 |
| 2024-09-17 | -0.04 |
| 2024-09-16 | -0.04 |
| 2024-09-13 | -0.04 |
| 2024-09-12 | -0.04 |